Clinical trial: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: ACTIVE_NOT_RECRUITING
Conditions: Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortical Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Neuroendocrine Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Low Grade Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Penile Squamous Cell Carcinoma|Peritoneal Mesothelial Neoplasm|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma
Interventions: PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|BIOLOGICAL: Ipilimumab|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Nivolumab
Study Type: INTERVENTIONAL
Study Design: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT